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Abstract: In keeping with the advance of biotechnology, cell culture becomes an 
important tool for investigating the transport and the metabolism phenomena.  A cell 
line of human origin, the BeWo choriocarcinoma cell line, was used for the study of the 
transport and metabolism of opioid peptides across the in vitro model of the placental 
barrier.  Opioid peptides, both naturally occurring and their synthetic analogs, are of 
interest to be developed as potent analgesics and were included in this study.  The 
apparent permeability coefficients of the peptides containing 4 to 11 amino acid or 
analog residues were in the range of 0.23-14.60 x 10-5 cm/sec.  The apparent 
permeability coefficients of these peptides were comparable to those of sucrose or 
dextrans, hydrophilic markers.  Molecular weight and size of the peptides were inversely 
correlated to the permeability across the BeWo monolayers.  Lipophilicity and charges 
of the peptides were also investigated and found to be the minor factors regulating the 
extent of peptide permeation.  Contrasting to the transport of DPDPE peptide analog 
across the blood-brain barrier, the transport of DPDPE across the BeWo monolayers 
were not found to be via carrier-mediated transport.  The major transport pathway of 
the opioid peptides across the BeWo monolayers was found to be via paracellular route.  
In metabolism studies, aminopeptidase was found to be a major enzyme type 
responsible for the degradation of naturally occurring peptides but not for the synthetic 
analogues.  The finding obtained from the present study reveal the applicability of the 
BeWo cell line to be used as the in vitro cell culture model for the transport and 
metabolism screening of the opioid peptides. 
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Introduction 
 
Since the discovery of multiple opioid receptors (1) and endogenous opioid 
peptides (2), several attempts have been made to synthesize safe and effective agonists to 
selective opioid receptors.  The clinically used µ-opioid receptor agonists such as 
morphine and meperidine are associated with side effects, which range from constipation 
to respiratory depression and dependence liability (3).  In addition, the above mentioned 
µ-receptor agonists have the ability to rapidly cross the placental barrier, thus posing a 
risk to the developing fetus.  
The developing fetus is not known to express the δ-opioid receptor (4).  
Therefore, selective δ-opioid receptor analogues can be developed without the risk of any 
adverse effects to the fetus.  The endogenous δ-opioid receptor-specific enkephalins (leu 
and met-enkephalins) have been shown to have significant analgesic properties (2).  
However, due to their high susceptibility to enzymatic degradation in vivo, attempts are 
being made to synthesize highly selective, enzymatically stable analogues of enkephalins 
which can be clinically used in the treatment of pain.  Mosberg et al. (5) reported the 
synthesis of several synthetic analogues of leu-enkephalin with high selectivity towards 
the δ-opioid receptor.  In addition, some of these peptides have shown good in vivo 
stability and appear to be promising candidates for the treatment of pain (6).  The blood-
brain barrier (BBB) transport of one synthetic analogue of leu-enkephalin, DPDPE, was 
found to be carrier-mediated (7).  However, no information currently exists on the 
placental transport and metabolism of these peptides.  
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The primary function of the placenta is to transport nutrients and excretory 
products to and from the fetus.  In addition, the placenta is also involved in the synthesis 
of hormones and steroids (8).  Although passive diffusion is the principal mechanism of 
transport across the placenta (9), several carrier-mediated transport mechanisms (e.g. for 
glucose, fatty acids and amino acids) have been identified (10, 11).  Several in vivo and in 
vitro models have been utilized to study the transport of substances across the placental 
barrier (12, 13).  However, in vitro models provide a simple and rapid method of studying 
the mechanistic aspects of drug transport.  Several cell lines (e.g. JAR, JEG and BeWo) 
have been evaluated for their potential applications in the study of the mechanisms of 
trans-trophoblast transport of drugs (14-16).  The BeWo cell line is a choriocarcinoma 
cell line developed from a malignant gestational choriocarcinoma of the fetal placenta 
and was characterized in 1968 (17).  This cell line has been shown to exhibit 
morphological and biochemical characteristics, similar to the human trophoblasts and the 
presence of nutrient and serotonin transporters (18-20) .  In addition, the BeWo cell line 
is stable, easy to maintain by passage and forms confluent monolayers on polycarbonate 
filters in a relatively short period of time (4-5 days), making it an attractive in vitro model 
to study trans-trophoblast transport, uptake and metabolism of drugs.    
Peptide transport across the placenta has not been studied extensively.  Of the few 
reported studies, the primary mechanism of peptide transport across the placenta appears 
to be via paracellular diffusion (21).  However, a low affinity transporter for dipeptides 
has been shown to exist (22).  The objectives of the present work were to investigate the 
trans-trophoblast transport of a series of opioid peptides and to determine the effect of 
physico-chemical properties (molecular size, molecular weight and lipophilicity) on their 
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transport across the trophoblast barrier.  In addition, the susceptibility of the peptides to 
enzymatic degradation and the mechanisms of transport of one synthetic analogue 
(DPDPE) across the trophoblast monolayers were also investigated.   
 
Materials and Methods 
 
Materials: 
Translucent polycarbonate filters (12 mm diameter, 0.4 µM pore size) were 
obtained from Fisher Scientific.  3H-DPDPE and 3H-DAMGO were obtained from 
DuPont-NEN Research (Boston, MA).  Amastatin ([(2S, 3R)-3-Amino-2-hydroxy-5-
methylhexanoyl]-Val-Val-Asp) was obtained from ICN (Cosa Mesta, CA).  Leu-
enkephalin (LE) was purchased from Sigma (St.Louis, MO).  All other peptides [Tyr-D-
Arg-Phe-D-Leu-NH2 (DADLE), Tyr-Tic-Phe-Phe (TIPP), Tyr-Ticψ[CH2-NH]-Phe-Phe 
(TIPP-ψ), Dynorphin A (1-11), Dynorphin A (2-11), Dynorphin A (1-8), Tyr-D-Ala-Gly-
N-Me-Phe-Gly-ol (DAMGO), Tyr-D-Arg-Phe-Lys-NH2 (DALDA), Tyr-D-Ser-Gly-Phe-
Leu-Thr (DSLET), and Tyr-[D-pen-Gly-Phe-D-Pen] (DPDPE)] were obtained from the 
National Institute on Drug Abuse (NIDA).  Dulbecco’s modified Eagles medium 
(DMEM), Hank’s balanced salt solutions (HBSS) and trypsin/EDTA solutions were 
purchased from Sigma.  Fetal bovine serum, heat activated (FBS/HI), was from JRH 
Biosciences (Lenexa, KS).  Penicillin/streptomycin as a mixture was obtained from 
GIB/Co. (Gaithersburg, MD).  Rat-tail collagen was prepared in our laboratory.  For 
performing the sensitive determinations of peptides [LE, Dynorphin A (1-11), Dynorphin 
A (2-11), and Dynorphin A (1-8)], 1H-naphtho(2,3-d)imidazole-6,7-dicarboxaldehyde 
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(IMNDA), a fluorogenic derivatizing reagent, was synthesized in our laboratory.  Sodium 
cyanide (NaCN) was purchased from Aldrich (St. Louis, MO).  All other chemicals were 
of the highest, commercially available grade. 
 
BeWo cell culture:  
The BeWo clone (b30) was obtained from Dr. Alan Schwartz (Washington 
University, St. Louis, MO).  The cells were cultured and harvested as previously 
described (23).  For transport studies, the cells were passed onto polycarbonate 
membranes coated with rat tail collagen.  At a seeding density of 100,000 cells/cm2, the 
cells formed monolayers in 4-5 days.  The medium was changed every other day and all 
cells used for these studies were from passages 35-90.  
 
Transmonolayer Permeability: 
Trans-monolayer permeability studies were carried out using a Side-Bi-Side 
diffusion apparatus (Crown Glass Company).  The donor and receiver chambers were 
each filled with 3.0 ml of PBSA (pH 7.4).  The cells faced the donor chamber as the 
apical (maternal) side and the membranes faced the receiver chamber as the basolateral 
(fetal) side.  The temperature during the studies was maintained at 37°C using 
thermostated water jacket.  The contents of the two chambers were stirred continuously at 
600 revolutions/min with magnetic stir bars to prevent the formation of an aqueous 
boundary layer.  Prior to the studies, the monolayer cultures were equilibrated for 30 
minutes.  Experiments were initiated by adding either 5 nM (3H-DPDPE and 3H-
DAMGO) or 100  
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µM of the other peptides (dissolved in PBSA) to the donor chamber.  A 100 µl sample 
was obtained from the receiver chamber at different time points over a 60 (3H-DPDPE 
and 3H-DAMGO) or 120 minute (all other peptides) period with replacement of the 
buffer after each sample withdrawal.  Samples were analyzed by liquid scintillation 
spectrometry (3H-DPDPE and 3H-DAMGO) using a Beckman scintillation counter (LS 
6800) or by HPLC.  In addition, transport experiments were conducted with 14C- sucrose, 
a marker for paracellular transport. Polycarbonate membranes treated with rat-tail 
collagen but without cell monolayers were used as a control.  The apparent permeability 
coefficients were estimated using the following equation: 
    P (cm/s) = X/(A * t * Cd)  
Where P is the apparent permeability coefficient, X is the amount of substance (mol) in 
the receiver chamber at time t (s), A is the diffusion area (0.636 cm2) and Cd is the 
concentration of the substance in the donor chamber (mol/cm3).  The permeability 
coefficients were expressed as the mean ± SD from three to six different monolayers.  
 The apparent permeability coefficients for the BeWo monolayers , Pe, were calculated 
from the following relationship; 
    1/Pt = 1/Pc + 1/Pe  
where Pt is the apparent permeability coefficients for the collagen-coated polycarbonate 
membranes in the presence of BeWo cell monolayers and Pc is the apparent permeability 
coefficients for collagen-coated polycarbonate membranes alone (24).   
In order to determine the mechanism of DPDPE transport across the BeWo 
monolayers, transport experiments (n = 4-6) of 5 nM 3H-DPDPE were carried out in the 
presence of excess (300 µM) unlabelled DPDPE.  In addition, to ensure that DPDPE was 
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not being metabolized by the enzymes of the BeWo cells during its transport, separate 
transport studies of 3H-DPDPE were conducted in the presence of an aminopeptidase 
inhibitor, amastatin (300 µM).  Apparent permeability coefficients for DPDPE were 
calculated in the presence and absence of amastatin.  
 
HPLC Analysis: 
Analysis of three peptides (DALDA, DADLE and DSLET) was conducted using 
reverse phase HPLC with UV detection. Samples (30 µl in triplicate) were injected on a 
4.5 X 250 mm C-18 column (Waters, Milford, MA) by an autoinjector (Shimadzu SIL-10 
AD).  The mobile phase consisted of a mixture of 0.1 M NaH2PO4 (containing 0.1% 
heptanesulfonic acid) and acetonitrile (75:25 v/v), pH 3.0 at 37°C at a flow rate of 1.5 
ml/min.  The eluting peptides were detected at a wavelength of 210 nm using a Shimadzu 
UV detector (SPD 6A) 
For performing a sensitive determination, reversed-phase HPLC with 
precolumn derivatization was optimized to determine the concentrations of LE and 
dynorphins.  The peptides were treated with IMNDA/NaCN to form fluorescent products.  
Subsequently, an aliquot of 50 µl of reaction mixture was injected onto HPLC column.  
Details of the analytical method were describes elsewhere (25).  A Spherisorb ODS (5 
µM, 80Å, 250 x 4.6 mm) column (Alltech, Deerfield, IL) was used for the determination 
of LE- and dynorphin-IMNDA(CN) derivatives.  Gradient elution with solution A [10% 
acetonitrile (ACN) in 0.05% TFA and 20 mM 1-heptane sulfonic acid (HSA)] and 
solution B [10% of 0.05% TFA and 20 mM 1-heptane sulfonic acid (HSA) in ACN] was 
performed with a linear gradient of 37% to 77% of solvent B within 20 minutes.  For 
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TIPP and TIPP-ψ determinations, an in-house packed Hypersil C18 (5 µM, 80Å, 150 x 
4.6 mm) was used in the study.  Isocratic elution with 28% ACN in 26 mM trifluoroacetic 
acid (TFA) was employed to elude the native form of TIPP and TIPP-ψ.  All separations 
were performed at an ambient temperature at the flow-rate of 1.0 ml/min.  Fluorescence 
detection was the technique employed either at λex = 467 nm and λem = 510 nm for the 
IMNDA derivatives or at λex = 208 nm and λem = 305 nm for the native TIPP and TIPP-
ψ peptides. 
 
Stability of Opioid Peptides upon Exposure to the BeWo Monolayers: 
The BeWo cells were seeded at 100,000 cells/cm2 into the 12 well tissue 
culture plates.  Collagen-coated polycarbonate membranes were not required in this 
study.  Cell maintenance was performed as described earlier; however, care was taken 
due to an easier detachment of the cell membranes from the plastic surface than the 
surface of the collagen-coated polycarbonate filters.  Since fully-grown or aged cells will 
detach easily from the plastic surface, the metabolism study was performed after the cells 
had grown to cover about 90% of the total surface.  The cell monolayers were washed 3 
times with 37°C phosphate buffer saline-ascorbic acid (PBSA) solution to eliminate other 
primary amines such as amino acids in cell culture media or other peptides that cells 
might have released to the medium.  Subsequently, the tissue culture plates were 
incubated in a temperature-controlled shaking water-bath (60 rpm, 37°C) for 10 minutes.  
Afterward, a peptide solution (25.0 µM) was added to each well including control wells, 
the wells without BeWo cell monolayers present.  Immediately after the addition of the 
peptide solution, peptide aliquots were withdrawn for the initial concentration 
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determination.  At 5, 15, 30, and 60 minutes, 176 µl aliquots were pipetted out from the 
subsequent wells.  The samples were collected in polypropylene vials and were then 
frozen immediately until the analysis. 
 
Lipophilicity: 
Utilization of the capacity factor (k´) from reversed-phase high-performance 
chromatography (RP-HPLC) has been reported for lipophilicity measurement (26, 27).  
In this study, the relative lipophilicity of the opioid peptides was determined from the 
ability of the peptides to interact with the immobilized artificial membrane (IAM).  An 
IAM chromatography column (4.6mm i.d. x 100 mm, 5 µm, 300 Å, Regis Technologies, 
Inc., Morton Grove, IL) with 5-10% ACN in 10 mM phosphate buffer as a mobile phase 
was used in determining of the ability of the peptides to interact with phosphatidylcholine 
(PC) analog membranes.  The PC analog membranes are the artificial membrane mimic 
the lipid environment found in cell membrane (28, 29).  A 20 µl aliquot of each peptide 
solution (100 µM) was injected on the column (flow rate 1.0 ml/min), and the eluate was 
detected with the UV (210 nm) detector (Shimadzu, Columbia, MD).  The IAM capacity 
factors (k′IAM) of the opioid peptides were calculated from the following equation: 
 
                         k′IAM = tR – t0  
        
          t0 
 
where tR is the retention time of a peptide and t0 is the column void volume.  Permeability 
coefficients were plotted against the k′IAM of the opioid peptides in order to evaluate the 
relationship between the relative lipophilicity of the peptides and ability to cross the 
BeWo monolayers. 
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Molecular Size: 
1H-NMR spectroscopy was utilized to determine the diffusion coefficients of 
the opioid peptides and analogues.  An opioid peptide in a concentration of 1 mM was 
dissolved in 10%D2O and 90% H2O.  A 500 MHz NMR spectrometer (Bruker AM-500) 
interfaced to an auxiliary PC-driven 15 ampere gradient pulse generator specifically 
designed for diffusion studies (Digital Specialties, Chapel Hill, NC) was employed in this 
study.  The NMR spectra were acquired using the pulsed field gradient bipolar 
longitudinal eddy current delay pulse sequence.  During the experiments, the diffusion 
delay time was held constant at 200 msec and the gradient pulse duration at 2 msec.  The 
gradient pulses was sequentially increased (i.e., 0.9, 1.4, 1.8, 2.6, 3.4, 4.2, 5.0 and 5.6 
msec) until one order of magnitude decreasing of a peak height of interest was observed.  
The experimental gradient strength was calculated from a coil constant of 5.15 G/cm/A 
based on the known diffusion coefficient of β-cyclodextrin at 25°C, 3.23 x 10-6 cm2/sec.  
By linear regression analysis, the diffusion coefficients at 25°C were obtained from the 
slope of the semilogaritm plots of the peak height versus the square of the pulse gradient.  
Applying the Stokes-Einstein equation, molecular radii (radius of gyration) of the 
peptides were calculated from their diffusion coefficients determined from the NMR 
experiments (30): 
 
D = kT/6πηr                    (Stokes-Einstein equation) 
where D is the diffusion coefficient (m2/sec), k is Boltzmann’s constant, T is the absolute 
temperature (K), r = the radius of a spherical particle and using viscosity (η) = 0.9183 
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centipoises calculated from the standard D and η of water at 25°C and D of 10%D2O and 
90% H2O at 25°C according to the square-root of mass law (31-33).  
 
Results and Discussion: 
 
Molecular Weight and Size of Peptides vs. Permeability Coefficients: 
Several in vivo and in vitro models have been used to study the trans-placental 
transport of nutrients and drugs (16, 34-36).  However, in vitro models could provide 
greater benefits in terms of speed and ease in the determination of the transport 
mechanisms and metabolism across barriers. The BeWo cell culture model has been 
shown to have morphological and biochemical characteristics similar to the human 
trophoblasts.  Unlike the placental primary cell cultures, the BeWo cell can be grown to 
confluent monolayers on rat tail collagen coated polycarbonate membranes with 4-5 days. 
These properties make the BeWo cell culture model an attractive in vitro model to study 
mechanisms of trans-trophoblast transport and metabolism of drugs.  
Although very few studies have been conducted, peptide transport across the 
placenta appears to be primarily via passive diffusion (21). The placenta, unlike the 
gastro-intestinal or the blood-brain barrier is a ‘leaky’ barrier and allows for a relatively 
free exchange of substances. The apparent permeability coefficients of most of the 
peptides studied (Table 1) were in the same range of the permeability coefficients of 
hydrophilic markers [14C-sucrose, fluorescein and fluorescein isothiocyanate conjugated 
dextrans (FITCDs).  The effect of peptide size was clearly shown to be an important 
factor in the transport study of dynorphin A series (1-11, 2-11 and 1-8), (Figure 1).  
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Dynorphin A (1-11) (M.W. 1363) was the least permeable across the BeWo monolayers. 
The inverse correlation between the Pe(s) and molecular weight (M.W.) of the peptides 
shown in Figure 2 indicates that the permeability of the peptides was highly dependent on 
their molecular weights and thus, their diffusivity in water.  Concerning various 
conformations of peptides in an aqueous solution, an investigation of the relationship 
between peptide permeability and their size may give more meaningful comparison than 
the correlation of their molecular weights.  Figure 3 shows the relationship between the 
apparent permeability coefficients and the molecular radii of the peptides determined 
from their diffusion coefficients using NMR spectroscopy technique.  Similar to the 
relationship between the permeability coefficients and the molecular weights, inverse 
linear correlation was observed.  The peptides with molecular weight > 800 daltons or 
molecular radii > 6 Å exhibit restricted permeation across the membranes.  For smaller 
peptides, poor relationships were found when either molecular weights or molecular size 
was employed indicating other factors such as lipophilicity, hydrogen bonding or peptide 
charge may influence the permeation properties of the peptides.  The excellent linear 
correlation between molecular weight and molecular radii of the peptides (R2 = 0.9444) 
suggesting molecular weight could be used interchangeably with molecular size as the 
parameter for the prediction of peptide permeability across the BeWo monolayers.  
  
Lipophilicity vs. Permeability Coefficients: 
Lipophilicity is another parameter that was investigated.  Immobilized artificial 
membrane (IAM) chromatography was selected to investigate the relative lipophilicity of 
the peptides.  IAM chromatography was employed for the evaluation of lipophilicity and 
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oral absorption ability of various drugs (29).  However, the utilization of this column is 
not suitable for the investigation of basic peptides such as dynorphin A (1-11), (2-11), (1-
8) and DALDA.  Although this column is filled with an end-capped packing material, the 
residual adsorption of positively charges of the basic peptides to the free silanol groups or 
perhaps to the negative charges of phosphate head groups of phosphatidylcholine analogs 
could be observed from the broad peaks of the basic peptides.  Figure 4a. shows the plot 
between the capacity factor (k´IAM) and the permeability coefficients of the opioid 
peptides.  A 10% ACN in 10 mM sodium phosphate, pH 7.4 was used as the mobile 
phase.  The results from these conditions are misleading, since the peptides containing 
multiple positive charges [i.e., dynorphin A(s)] were categorized as lipophilic 
compounds.  By including 2 mM 1-heptane sulfonic acid in an acidic mobile phase (10 
mM sodium phosphate buffer, pH 3.0), the ionic interactions between the positive 
charges of the peptides and the stationary phase were suppressed.  As shown in Figure 
4b., more reasonable results indicating TIPP, TIPP-ψ and a cyclic peptide (DPDPE) 
possessed lipophilic property were obtained.  A trend-line was drawn to show the 
relationship between k´IAM of lipophilic peptides and their permeability coefficients.  
Contrasting to the trend observed from the permeability across gastrointestinal (GI) 
barrier in which the more lipophilic compounds have greater permeability across the GI 
barrier (29), the inverse correlation of the k´IAM and the permeability across the BeWo 
monolayers was observed in this study.  In summary, the IAM column may not be 
appropriate for the determination of lipophilicity of basic compounds, since the 
interactions of analytes and stationary phase may cause false interpretations.  It may also 
be unsuitable for the prediction of the compounds which permeate through water-filled 
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channels, since the transport via this pathway is independent of the lipophilicity of 
analytes.  This finding suggests that the transport mechanism via transcellular route is not 
a major pathway for the permeation of peptides across the BeWo monolayers. 
As the peptides included in our study are relatively hydrophilic and their Pe(s) are 
comparable to those hydrophilic markers, restricted diffusion through water-filled 
transmembrane channels or pores which is a primary transport mechanism of most 
hydrophilic substances was suggested to be a major transport mechanism for these 
peptides.  In general, water-soluble drugs with molecular weights below 800 daltons (37) 
and perhaps closer to 1000 daltons (21, 38) appear to passively diffuse across the human 
placenta.  Similarly, the peptides included in our study whose molecular weights are 
higher than 1000, such as dynorphin A (1-11), (2-11) and (1-8), encountered some 
permeability difficulties due to a sieving property of the membrane.  These observations 
implied that the BeWo cell monolayers described by Liu et al. (23)  are likely to have 
similar permeability properties, such as pore size and porosity, to the human placental 
membrane.   
Due to the hydrophilic nature of these peptides, it is unlikely for them to be 
transported via a transcellular mechanism. However, additional experiments were carried 
out to determine whether a carrier-mediated mechanism exists in the trans-trophoblast 
transport of the opioid peptides.  Williams et al.(7) reported the presence of a saturable 
transport system involved in the BBB transport of DPDPE. Therefore studies were 
initiated to determine the trans-trophoblast transport of DPDPE using the in vitro cell 
culture model. The placenta is known to have significant amounts of peptidase activity 
(39, 40). Although DPDPE has been shown to be stable against enzymatic degradation, 
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the transport of 3H-DPDPE was studied in the presence of amastatin (50 µM). As seen 
from the data (Figure 5), the permeability coefficients of 3H-DPDPE were not influenced 
by the presence of an excess amount (300 µM) of unlabelled DPDPE or amastatin 
[(p<0.05) from 3H-DPDPE alone]. These studies show that DPDPE is resistant to 
enzymatic hydrolysis by the placenta and it’s primary mechanism of transport across the 
placenta is via passive diffusion.  
 Although a number of observations had been reported about the transport systems 
of nutrients and electrolytes across the placenta (37, 41), very limited information is 
available on peptide transport.  To date, one uptake study reported on the presence of 
very low affinity dipeptide transporter(s) found in brush-border membrane vesicles 
(BBMV) prepared from human full-term placenta (22).  However, these peptide 
transporters were not responsible for peptide uptake into human placental BBMV.  A 
simple diffusion mechanism was also suggested to be a transport pathway of oxytocin 
from the study using in vitro dually perfused isolated cotyledons from term human 
placenta (21).  While the other types of transport mechanisms remain unclear, an 
observation from our study suggested a possibility of the peptide transport via a 
transcellular route.  For all of the peptides included in this study, less than ten percent of 
the total amount of the peptides were observed in the receiver chambers.  Unlike other 
hydrophilic peptides, the permeation of rather lipophilic peptides, TIPP-ψ and TIPP, was 
observed with the lag-times of 5 and 30 minutes for TIPP-ψ and TIPP permeation, 
respectively.  From mass balance consideration, the recovery of most peptides was 
approximately one hundred percent; except for TIPP.  About 18% of TIPP were lost from 
the initial amount.  These observations suggested that a partial amount of TIPP could 
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remain adhered to the membrane and/or in the cells, implying that the transcellular 
transport could be a pathway for relatively hydrophobic peptides, such as TIPP in this 
case.  
Berhe et al. (42) reported the importance of charge effects on the permeability of 
positive or negative horseradish peroxidase across guinea-pig placenta.  Positively 
charged protein was found to permeate across the placenta better than the negatively 
charged protein.  However, no relationship between the charges and the permeability 
coefficients for the peptides was observed in this study.  Therefore, the changes of 
maternal and fetal plasma pH would not be expected to affect the permeability of these 
peptides. 
 
Stability of Opioid Peptides upon Exposure to BeWo Cell Monolayers: 
Aminopeptidases, carboxypeptidases, endopeptidases and dipeptidases were 
previously reported to be the enzymes responsible for degrading peptides in the human 
placenta.  Widely distributed in different parts of the placental cells, the transports of both 
naturally occurring and synthetic peptides are largely inhibited by peptidases (39, 40, 43).  
In this study, the naturally occurring opioid peptides, leu-enkephalin, dynorphin A (1-11) 
and the synthetic peptides, DADLE, TIPP and TIPP-ψ, were incubated with the BeWo 
cell monolayers at 37°C.  The surface area of a 12-well plate used in the metabolism 
study was larger than the surface area of Side-Bi-Side diffusion unit, and the 
degradation of the naturally occurring peptides became significant.  In the case of LE, 
although more than one site of the peptide bonds of LE is vulnerable to the enzymatic 
degradation, the major metabolite observed on the chromatogram was identified to be 
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des-Tyr-leu-enkephalin.  Des-Tyr-leu-enkephalin was also a primary metabolite of leu-
enkephalin found in rat jejunum (44) and in brain microvessel endothelial cells (BMEC) 
(45).  Rapid degradation was also observed for the dynorphin A (1-11), another naturally 
occuring opioid peptide (Figure 6).  The half-life of the intact dynorphin A (1-11) was 
found to be about 15 minutes.  The presence of aminopeptidases in the BeWo cells was 
also confirmed in this study.  The dynorphin A (1-11) was rapidly converted to several 
small fragments including des-Tyr peptide [dynorphin A (2-11)], which was the major 
identifiable metabolite.  The dynorphin A (2-11) was subsequently metabolized to other 
unidentified fragments.  Contrasting to the observation in plasma, dynorphin A (1-13) 
were 80% metabolized by carboxypeptidases (46), yielding dynorphin A (1-12).  In this 
study, dynorphin A (1-10) was found to be insignificant amounts upon the exposure of 
dynorphin A (1-11) to the BeWo cells, suggesting that aminopeptidases are the major 
enzymes in this cell type.  The peptidase activity in the BeWo cells was reported to be 
comparable to the activity in the placental cells from the primary cultures of the human 
cytotrophoblasts, however; the presence of gestation time, environment, smoking habits, 
drugs, metal and hormonal factors were shown to be important to the activity of the 
peptidases(40, 43).  In contrast to the naturally occurring peptide counterparts, the 
synthetic peptides, DADLE, TIPP and TIPP-ψ, were more stable upon incubation with 
the BeWo cells (Figure 7).  Therefore, the incorporation of unnatural amino acid residues 
into the peptide structures gave the peptides more resistance to placental enzyme 
degradation.  However, awareness should be made when the chemical modification of the 
peptide structure was adopted, since the ability of peptides to bind with opioid receptors 
is highly dependent on peptide stereochemistry (47).  The introduction of D-amino acid 
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residue(s) may compromise or change the binding selectivity to the receptors.  In 
addition, the presence of varieties of peptidases that can cleave at different sites of 
peptides increases the challenges to employ the chemical modification approach for the 
enhancement of peptide stability against enzymatic degradations. 
 
Conclusions: 
 
The BeWo cells served as both metabolic and physical barriers to the permeation 
of the peptides.  The permeation across the BeWo monolayers was highly dependent on 
molecular weights and molecular size of the peptides but not their lipophilicity and 
charge characters.  Therefore, the passage through the paracellular route was suggested to 
be a primary pathway for the transport of hydrophilic peptides.  However, the presence of 
peptidases in BeWo cells largely inhibited the distribution of the peptides across the 
BeWo placental barrier.  This study has confirmed the stability of structurally modified 
peptidomimetics in which peptides containing D-amino acid or unnatural residues were 
found to resist enzymatic degradation upon incubation with the BeWo cells.  Finally, 
information from this study can help explain the ability of peptides to penetrate the 
placental barrier and provides a basis for future designs of peptide molecules with 
minimal penetration through the placental barrier and minimal side-effects for obstetric 
analgesic applications. 
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Peptide Amino Acid Composition M.W. Permeability
coefficient x
105(cm/sec)
DAMGO Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol 513 11.90  2.90
Leu- Try-Gly-Gly-Phe-Leu 537 9.57  4.63
Enkephalin
DALDA Tyr-D-Arg-Phe-Lys-NH2 552 14.60  2.50
TIPP- Tyr-Tic[CH2NH]-Phe-Phe 618 5.99  0.62
DADLE Tyr-D-Ala-Gly-Phe-D-Leu 624 7.49  1.44
TIPP Tyr-Tic-Phe-Phe 634 4.93  0.60
DSLET Tyr-D-Ser-Gly-Phe-Leu-Thr 641 4.53  2.89 
DPDPE Tyr-[D-Pen-Gly-Phe-D-Pen](cyclic) 645 6.56  0.97
   Dynorphin A
(1-8)
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile 1033 4.19  2.40
Dynorphin A
(2-11)
Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-
Pro-Lys
1200 1.40  0.34
Dynorphin A Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile- 1363 0 23  0 04 
(1-11) Arg-Pro-Lys
.  .
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Plot showing the relationship between the molecular radii of model
peptides and the apparent permeability coefficients for permeation
across BeWo cell monolayers
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